Alzheimer’s disease is the most common cause of dementia in older adults. Till now, all the approved drug therapies of Alzheimer’s disease (AD) are only symptomatic. It simply means that the drugs will help in reducing some of the symptoms of AD such as memory loss, other cognitive and behavioral changes, and impairment in the daily routine activities. The limitation of these therapies is that they do not alter the course of the illness.

Now, numerous molecules with potential disease-modifying effects are under investigation. Many of these compounds interfere with disease pathogenesis and alter its progression. The new compound can be subdivided on the basis of their principal presumed target in AD such as:

  1. Amyloid beta
  2. Oxidative stress
  3. Inflammation
  4. Others

Current studies are also considering the use of currently approved compounds, natural compounds, compounds approved for other medical conditions that may produce some benefit in AD and novel compounds.

In medical therapy, NSAIDs, GAG mimetics and amyloid beta antibodies are under investigation. And various clinical trials are going on to prove the efficacy and safety of these compounds in AD. Among natural compounds antioxidants such as resveratol, curcumin, green tea catechins and docosahexanoic acid (DHA) are in various stages of clinical development.